GPx3 is considered to be a novel tumor suppressor, since hypermethylation of the GPx3 was detected in tumor samples from patients with Barrett’s esophagus [92-94], endometrial [95] and prostate cancer [96], and down-regulation was generally correlated with worse prognosis. This evidence concerns the gene GPX3 and neoplasm.